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CASE REPORT
Primary Granulocytic Sarcoma of the Face
Jong Ik Hwang, M.D., Tae Yoon Kim, M.D.
Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
Myeloid sarcoma is a tumor which consists of myeloblasts or 
immature myeloid cells. This tumor presents in the lymphoid 
organs, bone, skin, soft tissue, various mucosae and organs, 
and the central nervous system. Granulocytic sarcoma, an 
extramedullary acute myeloid leukemia, is also referred to as 
chloroma (GS) because of its greenish surface color. 
Granulocytic sarcoma is rare and difficult to diagnose. We 
can easily misdiagnose this tumor as lymphoma or sarcoma, 
especially when there is no evidence of hematologic 
disorders. Immunohistochemical studies are helpful in 
determining the correct diagnosis. Antibodies to myelo-
peroxidase, lysozyme, and chloroacetate esterase are used 
for the diagnosis of granulocytic sarcoma. In addition, 
detection of cell surface markers such as CD 33, CD 34, CD 
68, CD 99, and HLA-DR may be useful. We describe a case 
of GS that presented with bluish nodules on the right cheek 
of a 54-year-old woman with immunohistochemical findings 
for correct diagnosis. (Ann Dermatol 23(S2) S214∼S217, 
2011)
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INTRODUCTION
Myeloid sarcoma refers to a tumor formed by myeloblasts 
or immature myeloid cells that affects an extramedullary 
site or soft tissue, such as the skin. The mass, also referred 
to as an extramedullary myeloid tumor, granulocytic 
sarcoma, or chloroma, may precede aleukemic leukemia, 
or present simultaneously with a systemic myelopro-
liferative disorder or represent a relapse of a disease 
previously in remission
1. The term 'chloroma' has been 
used to describe this disease due to the green hue emitted 
by the myeloperoxidase (MPO) produced by these tumor 
cells
2. However, granulocytic sarcoma (GS) is the preferred 
term nowadays because not all of these tumors are green
3. 
Herein, we report an unusual case of GS of the face in a 
patient without leukemia.
CASE REPORT
A 54-year-old female patient presented in July 2009 with 
several facial lesions located on the right cheek for the 
past 4 years. The lesions were 0.5∼1.0 cm-sized light 
brownish to bluish nodules and a 2.0 cm-sized bluish 
plaque (Fig. 1). She had suffered from nasal congestion for 
about 1 year. There were a few polyps in the nasal cavity 
which were biopsied at another clinic. The biopsy tissues 
were diagnosed as myeloid sarcoma in the nasal cavity 
and were completely removed by excision several weeks 
earlier at our hospital. The paranasal sinus computed 
tomography results before excision showed granulation 
tissue in the nasal cavities. Following histopathologic 
examination, the excision tissues from the nasal cavities 
were revealed to be myeloid sarcoma. Hematologic study 
showed a leukocyte count of 4,870/μl with normal 
differential count. Bone marrow aspiration results showed 
no evidence of increased blast count. Histopathologic 
examination of the skin lesions revealed atypical lympho-
proliferation (Fig. 2). The results of immunohistochemi-
stries for CD 3, CD 4, CD 8, CD 20, CD 23, and CD 5a, Primary Granulocytic Sarcoma of the Face
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Fig. 1. Several brownish to bluish 
nodules and plaque on the right 
cheek and temple.
Fig. 2. Photomicrograph of biopsy sections showing infiltration of immature myeloid cells to dermis (H&E: ×40, ×100, ×400).
which are B- and T-cell markers, were negative. The 
results showed that the tumor was not lymphoma. We 
also attempted further immunohistochemical examination 
with antibodies to MPO, CD 68, and CD 99 (Fig. 3), and 
the results were all positive. From these findings we 
diagnosed these lesions as granulocytic sarcoma. The 
patient was transferred to the hematologic department and 
treated with idarubicin and cytarabin, which are used for 
acute myelogenous leukemia (AML) treatment. One year 
after induction and consolidation chemotherapy, hematologic 
analysis revealed a leukocyte count of 2,490/μl with no 
evidence of systemic leukemia and relapsed cutaneous 
tumor.
DISCUSSION
GS is an extramedullary leukemia tumor, that includes 
leukemia cutis and meningeal leukemia. GS is characterized 
by localized infiltration of immature granulocytes in an 
extramedullary site or soft tissue. GS was first described in 
the early 1800s as a tumor on the retro-orbital site with a 
green-colored appearance, which caused proptosis
4. The 
term "chloroma" is derived from the Greek word chloros 
(green) and was used by King
2 in 1853. In 1967, 
Rappaport
3 referred this tumor as GS because not all of 
the tumors were green. 
In many cases, GS occurs in childhood with one JI Hwang, et al
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Fig. 3. Positive staining for myeloperoxidase, CD 68 and CD 99 in granulocytic sarcoma cells of the skin (×400). MPO: myeloperoxidase.
rapid-growing mass, but also presents as multiple lesions. 
It is generally seen in the ribs, sternum, pelvis, orbital 
bone, soft tissues, lymph nodes, skin, and gums. It also 
involves the spine, small intestine, orbit, cervix, and nasal 
sinuses. GS occurs at any age, but some reports suggest a 
wide age range with a mean onset during middle age
5. 
There is no sexual predilection for GS.
Clinically, GS can occur in the following three scenarios: 
1) AML or other bone marrow and blood involvement, 2) 
isolated recurrence of AML or as a sign of blast trans-
formation in patients with chronic myelogenous leukemia 
(CML), and 3) before the presence of systemic leukemia, 
as a harbinger for AML
6. GS is found in only 3% to 8% of 
leukemia patients and is associated with AML and chronic 
myeloproliferative disorder (CMPD). It can also occur as a 
precursor to AML rarely without any evidence of a 
hematological disorder
7. The primary GS is a rare 
condition that occurs in the absence of any past history of 
leukemia and is commonly misdiagnosed as lymphoma or 
sarcoma. One report showed that misdiagnosis occurred 
in 47% (72 out of 154 cases of primary extramedullary 
leukemia) of cases, and another study reported an incident 
rate of 56% (34 cases in 61 biopies of 50 patients) of 
misdiagnosis
8. Thus, immunohistochemical studies must 
be evaluated for correct diagnosis.
Histologically, GS undergoes various morphological 
changes in the cells. It is composed of immature cells of 
the neutrophil granulocytic series. The infiltration of 
immature, poorly differentiated cells with round to oval 
nuclei is the predominant finding. Crystalline, rod-like, 
intracytoplasmic acidophilic bodies called Auer rods are 
sometimes seen
9. With these histological findings, it is 
hard to distinguish GS from other lymphomas including 
histiocytic lymphoma, lymphoblastic lymphoma, Ewing’s 
sarcoma, lymphocytic leukemia, undifferentiated carcino-
mas, and primitive neuroectodermal tumors
10. B-and 
T-cell markers (CD 45, CD 20, UCHL-1, CD 3, and CD 
30) would be helpful to rule out a diagnosis of lymphoma. 
Definitive diagnosis requires histochemical stains to 
demonstrate the presence of MPO. Anti-lysozyme and 
chloroacetate esterase can also be used to diagnose GS. 
Sudan black B, peroxidase or diaminobenzidine reactions 
are used to identify MPO. MPO is localized in the primary 
granules of the myeloid cells and is synthesized early in 
differentiation, thus serving as an important marker for 
myeloid lineage
11. Other monoclonal antibodies to the 
membrane surface or cytoplasmic antigens such as CD 33, 
CD 34, CD 68, CD 99, and HLA-DR can also be useful
12. 
In our case, positive results were obtained for antibodies 
to myeloid cells such as anti-MPO, anti-CD 68, and 
anti-CD 99. MPO is a valuable marker and a positive 
outcome means that this tumor is a myeloblastic variant. 
CD 68 positive shows that the tumor cells are of mono-
cytic and granulocytic lineages. CD 99 is expressed by a 
significant proportion of myeloid sarcomas. Additionally, 
a positive TdT stain indicates immature or nondifferen-
tiated tumor cells. A special stain for Leder Reaction can 
result in a focally positive outcome. We were easily able 
to diagnose GS with these immunohistochemical results.
There are multiple predisposing factors for the develop-
ment of primary and secondary GS. Cytogenetic abnor-
malities including t(8;21), inv(16), FAB subtypes M4 and Primary Granulocytic Sarcoma of the Face
Vol. 23, Suppl. 2, 2011 S217
M5, high white blood cell count, the presence of NCAM 
and/or T-cell markers (CD 2, CD 4, or CD 7), and poor 
nutrition and low socioeconomic status have been 
suggested to associate with GS development
8.
The prognosis of GS is not very good. Its course is rapid 
and it has a high mortality rate, especially when 
associated with AML
13. Patients without evidence of 
leukemia have a better outcome. Cases initially diagnosed 
as GS without evidence of leukemia and treated with 
systemic chemotherapy are likely to have a lower 
probability of developing acute myeloid leukemia and 
were shown to be associated with longer survival rates
14. 
However, patients who received no chemotherapy had a 
higher chance of developing leukemia after diagnosis of 
GS without hematologic abnormality at the initial 
diagnosis
15. Furthermore, early systemic therapy was 
shown to be helpful to prevent AML development and 
resulted in longer overall survival
14. Therefore, GS should 
be treated early in the course of the disease with systemic 
treatment. Irradiation therapy is also used for primary GS. 
Although radiotherapy is effective for high radiosensitivity, 
it does not improve disease free survival and prognosis. It 
is suggested that GS is a systemic disease and resection or 
irradiation treatment should be combined with intensive 
chemotherapy
16. In the Korean literature, three cases of 
cutaneous GS have been reported
17,18. In two such cases, 
skin lesions developed in patients with AML, and in 
another case, cutaneous GS was found before the 
presence of systemic leukemia
17,18.
We clinically experienced a case of GS arising on the 
face, and there was no association with leukemia. 
Immunohistochemical studies have been helpful for 
making the correct diagnosis. Primary GS may be a 
harbinger for leukemia; therefore, we should cautiously 
conduct patient follow up and look out for the 
development of leukemia. At 1 year follow up after 
systemic chemotherapy, the patient had no evidence of 
cutaneous recurrence and development of systemic 
leukemia.
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